" "

Serum Institute of India acquires 20% stake in IntegriMedical to advance Needle Free Injection System technology

ISN Team
Updated On
New Update
Serum Institute of India acquires 20% stake in IntegriMedical

Serum Institute of India (SII), the world's largest vaccine manufacturer, today said it is acquiring 20% stake in IntegriMedical to advance Needle-Free Injection System technology.

The company said the partnership aligns with the vision of 'Health for All' and IntegriMedical's mission to ‘Transform Healthcare Globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion. 

Developed a US-patented needle-free injection system

IntegriMedical has developed a US-patented Needle-Free Injection System (N-FIS) that utilizes a high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs.


The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience.

Leadership comments

"At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide. IntegriMedical's Needle-Free Injection Systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines," said Adar Poonawalla, CEO, of Serum Institute of India.

"We believe, this could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients & healthcare professionals," Poonawalla added.

 "We are excited to have Serum Institute of India as our strategic partner," said Sarvesh Mutha, MD, IntegriMedical.

"This investment is a testament to the potential of our Needle-Free Injections System technology and its ability to revolutionize drug delivery. SII's expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide,” he added.

N-FIS's regulatory approvals

IntegriMedical’s Needle-Free Injection System, also known as N-FIS, has received regulatory approvals from CDSCO, CE, and MDSAP and is ISO 13485 certified. 

Additionally, the technology is patented in the United States, the company said in a release.

IntegriMedical's MD, Ankur Naik, has been instrumental in the development and clinical trials of the N-FIS technology, demonstrating its effectiveness in reducing pain and eliminating needle phobia in patients.

Expanding access to care and improving efficiencies

The collaboration between SII and IntegriMedical leverages the strengths of both companies.

SII brings its extensive expertise in vaccine manufacturing and global distribution, while IntegriMedical contributes its innovative drug delivery technology and research capabilities.

Both companies aim to expand access to care and improve efficiencies in the global healthcare industry.

N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections.

The technology's advantages include the elimination of needle-phobia, alleviation of pain during administration, the convenience of use, and prevention of needle-stick injuries and cross-contamination.